Adeno-associated virus vectors serotype 2 induce prolonged proliferation of capsid-specific CD8 T cells in mice

Molecular Therapy

Volumn 19, Issue 3, 2011, Pages 536-546

  Li, Hua ^a   Tuyishime, Steven ^a,b   Wu, Te Lang ^a,b   Giles Davis, Wynetta ^a   Zhou, Dongming ^a   Xiao, Weidong ^c   High, Katherine A ^d   Ertl, Hildegund C J ^a,b  

^a WISTAR INSTITUTE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 9; EPITOPE; PARVOVIRUS VECTOR; PROTEIN VP2; PROTEIN VP3; VIRUS CAPSID ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CD8+ T LYMPHOCYTE; CELL EXPANSION; CELL ISOLATION; CELLULAR IMMUNITY; CONTROLLED STUDY; DENDRITIC CELL; FEMALE; IMMUNIZATION; IN VIVO STUDY; LIVER CELL; LYMPHOCYTE PROLIFERATION; MALE; MOUSE; NONHUMAN; VIRAL GENE DELIVERY SYSTEM; VIRUS CAPSID;

ADENO-ASSOCIATED VIRUS; MIRIDAE; MUS;

EID: 79952195654     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2010.267     Document Type: Article

References (33)

1. Manno, CS, Pierce, GF, Arruda, VR, Glader, B, Ragni, M, Rasko, JJ et al. (2006). Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med 12: 342-347. (Pubitemid 43355084)
2. Arruda, VR, Schuettrumpf, J, Herzog, RW, Nichols, TC, Robinson, N, Lotf, Y et al. (2004). Safety and effcacy of factor IX gene transfer to skeletal muscle in murine and canine hemophilia B models by adeno-associated viral vector serotype 1. Blood 103: 85-92. (Pubitemid 38029922)
3. Herzog, RW, Yang, EY, Couto, LB, Hagstrom, JN, Elwell, D, Fields, PA et al. (1999). Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector. Nat Med 5: 56-63. (Pubitemid 29050999)
4. Mount, JD, Herzog, RW, Tillson, DM, Goodman, SA, Robinson, N, McCleland, ML et al. (2002). Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy. Blood 99: 2670-2676. (Pubitemid 34525351)
5. Scallan, CD, Lillicrap, D, Jiang, H, Qian, X, Patarroyo-White, SL, Parker, AE et al. (2003). Sustained phenotypic correction of canine hemophilia A using an adeno-associated viral vector. Blood 102: 2031-2037. (Pubitemid 37122376)
6. Brantly, ML, Chulay, JD, Wang, L, Mueller, C, Humphries, M, Spencer, LT et al. (2009). Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy. Proc Natl Acad Sci USA 106: 16363-16368.
7. Mingozzi, F, Maus, MV, Hui, DJ, Sabatino, DE, Murphy, SL, Rasko, JE et al. (2007). CD8(+) T-cell responses to adeno-associated virus capsid in humans. Nat Med 13: 419-422. (Pubitemid 46559826)
8. Mingozzi, F, Meulenberg, JJ, Hui, DJ, Basner-Tschakarjan, E, Hasbrouck, NC, Edmonson, SA et al. (2009). AAV-1-mediated gene transfer to skeletal muscle in humans results in dose-dependent activation of capsid-specifc T cells. Blood 114: 2077-2086.
9. Li, H, Lin, SW, Giles-Davis, W, Li, Y, Zhou, D, Xiang, ZQ et al. (2009). A preclinical animal model to assess the effect of pre-existing immunity on AAV-mediated gene transfer. Mol Ther 17: 1215-1224.
10. Li, H, Murphy, SL, Giles-Davis, W, Edmonson, S, Xiang, Z, Li, Y et al. (2007). Pre-existing AAV capsid-specifc CD8+ T cells are unable to eliminate AAV-transduced hepatocytes. Mol Ther 15: 792-800. (Pubitemid 46432000)
11. Wang, L, Figueredo, J, Calcedo, R, Lin, J and Wilson, JM (2007). Cross-presentation of adeno-associated virus serotype 2 capsids activates cytotoxic T cells but does not render hepatocytes effective cytolytic targets. Hum Gene Ther 18: 185-194. (Pubitemid 46626458)
12. Jiang, H, Couto, LB, Patarroyo-White, S, Liu, T, Nagy, D, Vargas, JA et al. (2006). Effects of transient immunosuppression on adenoassociated, virus-mediated, liver-directed gene transfer in rhesus macaques and implications for human gene therapy. Blood 108: 3321-3328.
13. Lin, SW, Hensley, SE, Tatsis, N, Lasaro, MO and Ertl, HC (2007). Recombinant adeno-associated virus vectors induce functionally impaired transgene product-specifc CD8+ T cells in mice. J Clin Invest 117: 3958-3970. (Pubitemid 350224105)
14. Kelly, JM, Sterry, SJ, Cose, S, Turner, SJ, Fecondo, J, Rodda, S et al. (1993). Identifcation of conserved T cell receptor CDR3 residues contacting known exposed peptide side chains from a major histocompatibility complex class I-bound determinant. Eur J Immunol 23: 3318-3326. (Pubitemid 23353785)
15. Jung, S, Unutmaz, D, Wong, P, Sano, G, De los Santos, K, Sparwasser, T et al. (2002). In vivo depletion of CD11c+ dendritic cells abrogates priming of CD8+ T cells by exogenous cell-associated antigens. Immunity 17: 211-220. (Pubitemid 35245963)
16. Ertl, HC (2005). Challenges of immune responses in gene replacement therapy. IDrugs 8: 736-738. (Pubitemid 41269361)
17. Li, C, Hirsch, M, Asokan, A, Zeithaml, B, Ma, H, Kafri, T et al. (2007). Adeno-associated virus type 2 (AAV2) capsid-specifc cytotoxic T lymphocytes eliminate only vector-transduced cells coexpressing the AAV2 capsid in vivo. J Virol 81: 7540-7547. (Pubitemid 47047840)
18. Li, C, Hirsch, M, DiPrimio, N, Asokan, A, Goudy, K, Tisch, R et al. (2009). Cytotoxic-T-lymphocyte-mediated elimination of target cells transduced with engineered adeno-associated virus type 2 vector in vivo. J Virol 83: 6817-6824.
19. Madsen, D, Cantwell, ER, O'Brien, T, Johnson, PA and Mahon, BP (2009). Adeno-associated virus serotype 2 induces cell-mediated immune responses directed against multiple epitopes of the capsid protein VP1. J Gen Virol 90(Pt 11): 2622-2633.
20. Sabatino, DE, Mingozzi, F, Hui, DJ, Chen, H, Colosi, P, Ertl, HC et al. (2005). Identifcation of mouse AAV capsid-specifc CD8+ T cell epitopes. Mol Ther 12: 1023-1033. (Pubitemid 41723036)
21. Li, C, Goudy, K, Hirsch, M, Asokan, A, Fan, Y, Alexander, J et al. (2009). Cellular immune response to cryptic epitopes during therapeutic gene transfer. Proc Natl Acad Sci USA 106: 10770-10774.
22. Lasaro, MO, Tatsis, N, Hensley, SE, Whitbeck, JC, Lin, SW, Rux, JJ et al. (2008). Targeting of antigen to the herpesvirus entry mediator augments primary adaptive immune responses. Nat Med 14: 205-212. (Pubitemid 351214551)
23. Lanzavecchia, A and Sallusto, F (2001). Antigen decoding by T lymphocytes: from synapses to fate determination. Nat Immunol 2: 487-492. (Pubitemid 33705849)
24. Hamilos, DL (1989). Antigen presenting cells. Immunol Res 8: 98-117. (Pubitemid 19135914)
25. Mingozzi, F and High, KA (2007). Immune responses to AAV in clinical trials. Curr Gene Ther 7: 316-324. (Pubitemid 47595774)
26. Masopust, D, Ha, SJ, Vezys, V and Ahmed, R (2006). Stimulation history dictates memory CD8 T cell phenotype: implications for prime-boost vaccination. J Immunol 177: 831-839. (Pubitemid 44036583)
27. Davis, MM (2008). A prescription for human immunology. Immunity 29: 835-838.
28. Gao, G, Vandenberghe, LH and Wilson, JM (2005). New recombinant serotypes of AAV vectors. Curr Gene Ther 5: 285-297. (Pubitemid 40895013)
29. Li, W, Asokan, A, Wu, Z, Van Dyke, T, DiPrimio, N, Johnson, JS et al. (2008). Engineering and selection of shuffed AAV genomes: a new strategy for producing targeted biological nanoparticles. Mol Ther 16: 1252-1260. (Pubitemid 351866056)
30. McCarty, DM (2008). Self-complementary AAV vectors; advances and applications. Mol Ther 16: 1648-1656.
31. Zhong, L, Li, B, Mah, CS, Govindasamy, L, Agbandje-McKenna, M, Cooper, M et al. (2008). Next generation of adeno-associated virus 2 vectors: point mutations in tyrosines lead to high-effciency transduction at lower doses. Proc Natl Acad Sci USA 105: 7827-7832. (Pubitemid 351872723)
32. Kloetzel, PM (2004). The proteasome and MHC class I antigen processing. Biochim Biophys Acta 1695: 225-233.
33. Hauck, B, Murphy, SL, Smith, PH, Qu, G, Liu, X, Zelenaia, O et al. (2009). Undetectable transcription of cap in a clinical AAV vector: implications for preformed capsid in immune responses. Mol Ther 17: 144-152.